# *Helicobacter pylori* chronic infection and mucosal inflammation switches the human gastric glycosylation pathways

**Ana Magalhães**[a,b], **Ricardo Marcos-Pinto**[c,d,e], **Alison V. Nairn**[f], **Mitche dela Rosa**[f], **Rui M. Ferreira**[a,b], **Susana Junqueira-Neto**[a,b], **Daniela Freitas**[a,b], **Joana Gomes**[a,b], **Patrícia Oliveira**[a,b], **Marta R. Santos**[b], **Nuno T. Marcos**[a,b,g], **Wen Xiaogang**[h,i], **Céu Figueiredo**[a,b,e], **Carla Oliveira**[a,b,e], **Mário Dinis-Ribeiro**[e,j,k], **Fátima Carneiro**[a,b,e,h], **Kelley W. Moremen**[f], **Leonor David**[a,b,e], and **Celso A. Reis**[a,b,d,e,*]

[a]Institute for Research and Innovation in Health (i3S), University of Porto, Portugal

[b]Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Portugal

[c]Centro Hospitalar do Porto (CHP), Gastroenterology Department, Portugal

[d]Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Portugal

[e]Medical Faculty, University of Porto, Portugal

[f]Complex Carbohydrate Research Center and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA, USA

[g]Section of Health Sciences, University of Aveiro, Portugal

[h]Department of Pathology, Centro Hospitalar São João, Porto, Portugal

[i]Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

[j]Gastroenterology Department, IPO Porto, Portugal

[k]CIDES/CINTESIS, University of Porto, Portugal

## Abstract

*Helicobacter pylori* exploits host glycoconjugates to colonize the gastric niche. Infection can persist for decades promoting chronic inflammation, and in a subset of individuals lesions can silently progress to cancer. This study shows that *H. pylori* chronic infection and gastric tissue inflammation result in a remodeling of the gastric glycophenotype with increased expression of sialyl-Lewis a/x antigens due to transcriptional up-regulation of the *B3GNT5, B3GALT5*, and

[*]Corresponding author at: IPATIMUP, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal. celsor@ipatimup.pt (C.A. Reis).

**Contributors**

AM and CAR conceived and designed research experiments and wrote the paper; RMP collected the gastric biopsies; experiments were performed by AM, AVN, MR, SN, DF, RMF, JG and MRS; LD, WX and FC performed histopathological and immunohistochemistry analysis; PO and CO performed the bioinformatics analysis; AM, AVN, LD, KWM and CAR analyzed the data; AVN, LD, CF, NTM, CO, MDR, FC and KWM contributed reagents, materials and revised the manuscript.

**Transparency document**

The Transparency document associated with this article can be found, in the online version.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.bbadis.2015.07.001.

*FUT3* genes. We observed that *H. pylori* infected individuals present a marked gastric local proinflammatory signature with significantly higher TNF-α levels and demonstrated that TNF-induced activation of the NF-kappaB pathway results in B3GNT5 transcriptional up-regulation. Furthermore, we show that this gastric glycosylation shift, characterized by increased sialylation patterns, favors SabA-mediated *H. pylori* attachment to human inflamed gastric mucosa. This study provides novel clinically relevant insights into the regulatory mechanisms underlying *H. pylori* modulation of host glycosylation machinery, and phenotypic alterations crucial for life-long infection. Moreover, the biosynthetic pathways here identified as responsible for gastric mucosa increased sialylation, in response to *H. pylori* infection, can be exploited as drug targets for hindering bacteria adhesion and counteract the infection chronicity.

**Keywords**

*Helicobacter pylori*; Chronic infection Glycophenotype; Sialic acid-binding adhesin

## 1. Introduction

Gastric cancer is a public health burden worldwide, being the third leading cause of cancer-related mortality. The Lauren intestinal-type tumors constitute the most frequent form of gastric adenocarcinomas, and commonly arise in the context of a carcinogenic pathway initiated by chronic inflammation of the gastric mucosa triggered by *Helicobacter pylori* (*H. pylori*) infection [1]. *H. pylori* is classified as a carcinogenic agent by the WHO, and epidemiological studies show that 1–3% of infected individuals ultimately develop gastric cancer, which corresponds to a million new cases every year [2].

Disease development depends on bacterial ability to establish close contact with the gastric epithelial cells and to transfer virulence factors [3]. One of the proteins translocated into the host cells is the cytotoxin-associated gene A (CagA) protein, which is phosphorylated by host kinases and interferes with key signal transduction pathways [4]. Individuals infected with *cagA*-positive strains present increased risk for development of severe disease outcomes, including gastric cancer [5,6].

Bacterial attachment is mediated by outer membrane adhesins that bind to glycoconjugates present in the gastric mucus layer and lining the surface epithelium of the gastric mucosa [7]. The blood group antigen binding adhesin (BabA) recognizes ABO(H)/Lewis b blood group antigens expressed in glycoproteins from the gastro-intestinal tract by secretor individuals [8–10], whereas the sialic acid binding adhesin (SabA) mediates bacterial attachment through binding to α2,3-sialylated structures, such as sialyl-Lewis a (sialyl-Le[a]) and sialyl-Lewis x (sialyl-Le[x]) carried by glycosphingolipids and glycoproteins [11]. The *babA* gene shares regions of high homology with the *babB* and *babC* genes. It has been demonstrated that bacteria presenting inactive BabA can gain Lewis b binding properties by *babA* and *babB* gene recombination [12]. Recently, a novel *H. pylori* adhesin has been identified, the LacdiNAc-specific adhesin (LabA), which recognizes di-*N*-acetyllactosamine (lacdiNAc) motifs, carried by MUC5AC gastric mucin [13]. The myriad of receptors that can be exploited by *H. pylori* to adhere to the gastric mucosa reflects the multiple target

strategy adopted by this bacterium to efficiently colonize the gastric niche and maintain a chronic infection.

Glycan-mediated adhesion of *H. pylori* to gastric epithelial cells has been shown to act as an important trigger for translocation of bacterial virulence factors into the host cells [14]. The translocation of effector molecules, such as CagA and the bacterial cell wall peptidoglycan (PGN), results in the modulation of different host intracellular signaling pathways, including stimulation of the NF-κB (nuclear factor κB) pathway [15,16].

*H. pylori* induced inflammatory responses include the up-regulation of proinflammatory cytokines, including IL-8 and TNF-α. Concomitantly with the gastric mucosal inflammation, the human gastric glycosylation patterns change with expression of inflammation associated sialylated glycans [11,17,18]. Importantly, inflammation has been shown to modulate the expression of the glycosyltransferases involved in the biosynthesis of terminal glycan chains [19–21]. However, little is known about the molecular mechanisms governing the glycosylation shift that occurs in gastric mucosa in response to infection.

We have previously shown that *H. pylori* induces, in human gastric cell lines, the expression of β3GnT5, a GlcNAc-transferase that drives the biosynthesis of the SabA-ligand sialyl-Le$^x$ [22]. However, the activation of this glycosylation pathway, as well as the existence of other regulatory mechanisms underlying these glycophenotypic changes, in the complex context of human *H. pylori* chronic infection, have never been addressed.

To assess the effect of chronic *H. pylori* infection and gastric mucosa inflammation on the transcriptional regulation of the enzymes that determine the host gastric cell's glycophenotype, we have evaluated the glycosylation and the glycosyltransferase transcriptomic profile of gastric biopsies from healthy and infected individuals. In addition, we have determined the transcript levels of inflammation markers in gastric tissues and determined the effects of TNF-α proinflammatory cytokine, as well as downstream signaling pathways in the transcriptional regulation of the *B3GNT5* gene. Furthermore, we have determined the functional impact of these glycophenotypic alterations on *H. pylori* ability to attach to the gastric mucosa.

## 2. Material and methods

### 2.1. Human gastric tissue samples

This study includes 50 individuals, who were part of a case–control study that encompassed first-degree relatives of patients with early-onset gastric carcinoma (n = 26) and controls that comprised spouses (n = 14) and neighbors (n = 4) of the cases and dyspeptic patients (n = 6) (Supplementary Table 1) [23]. All individuals underwent high definition upper GI endoscopy at Centro Hospitalar do Porto (CHP, Porto, Portugal). Parallel biopsies were collected for RNA extraction, histopathological evaluation and *H. pylori* culture. Serum samples were also collected from all individuals at the time of endoscopy. This study was approved by the ethical committee of Centro Hospitalar do Porto (Portugal) and written informed consent was received from all participants.

## 2.2. Histopathological evaluation, H. pylori infection status and cagA genotyping

Gastric biopsy sections were stained with hematoxylin and eosin and modified Giemsa for histological examination by two pathologists who were blinded to the patient data and endoscopic findings. The tissue sections were evaluated based on updated Sydney–Houston classification system. *H. pylori* was cultured from fresh biopsies and genotyping of *cagA* was performed as previously described [24]. Individual serological values for anti-*H. pylori* IgG/IgA were determined according to standard protocol. Cases were classified as *H. pylori* positive when histology and culture from fresh biopsies were positive. There were two cases classified as *H. pylori* positive (based on histological observation and high anti-*H. pylori* IgG/IgA antibody titers) from which bacteria was not possible to cultivate *in vitro* and therefore the *cagA* status could not be determined (Fig. 1A and Supplementary Table 1).

## 2.3. Immunohistochemistry and lectin staining

Tissue staining of sialyl-Le$^a$ (CA19.9, Santa Cruz) and sialyl-Le$^x$ (KM93, Calbiochem) was performed as previously described [10]. The CA19.9 antibody detects sialyl-Le$^a$ and is routinely used in the clinics. Analysis of KM93 glycan epitope specificity showed that it is reactive to sialyl-Le$^x$ on core 2, but does not recognizes sialyl-Le$^x$ on core 3 [25]. Additionally, binding of KM93 to the non-fucosylated type 2 sialylated structures cannot be excluded as suggested by glycan array analysis from the Consortium for Functional Glycomics (http://www.functionalglycomics.org).

Detection of α2,6-sialylated glycans was performed using the SNA lectin (*Sambucus nigra*, Vector Laboratories) accordingly to the procedure previously described [10]. Tissue sections from antrum biopsies were used whenever possible. In two cases due to the presence of intestinal metaplasia (IM) in the antrum region, biopsies from incisura angularis were selected. Only cytoplasmic and membrane staining of the foveolar epithelium region was considered for expression evaluation. Expression in secreted mucus and IM areas was excluded from our analysis. Statistical analysis was performed using StatView 5.0 and significance determined using the Fisher's exact test.

## 2.4. Gastric biopsy transcriptomic analysis

Quantitative real-time PCR was performed as previously described [26]. Briefly, total RNA was isolated from frozen gastric biopsies using the RNeasy Plus Mini RNA isolation kit (Qiagen). A cDNA reaction for each sample was synthesized according to manufacturer's instructions using SuperScript III (Invitrogen), including a control reaction lacking reverse transcriptase for detection of contaminating genomic DNA. For qRT-PCR, the cDNA was used in triplicate reactions for each gene tested. The sequences of the primers used in this study are included in Supplementary Table 2. The relative transcript levels in each sample were determined using the Ct method. Due to the heterogeneous nature of the gastric biopsies, the relative transcript expression of all genes tested was normalized to the expression of the epithelial marker cytokeratin 18 (*KRT18*). Statistical analysis was performed using GraphPad PRISM 5.0 software and significance was evaluated by unpaired t test with Welch's correction (95% confidence interval).

## 2.5. Bioinformatic analysis

Using the Ensembl database [27], the nucleotide sequence corresponding to a CpG island (chr 3: 182970925–182972635) predicted to exist in the 5'UTR region of the human *B3GNT5* gene (ENSG00000176597) was extracted and analyzed with the software package PROMO [28] for transcription factor binding site prediction. Default matrices were used and factors predicted within a dissimilarity margin less or equal than 15%, corresponding to NF-κB [T00590] and NF-κB1 [T00593] were selected. The same CpG island sequence was screened for DNase I hypersensitive sites using Ensembl database [27] and nucleotide sequence conservation across the genomes of *Homo sapiens, Pan troglodytes, Gorilla gorilla, Pongo abelii, Callithrix jacchus* and *Mus musculus*.

## 2.6. Human gastric cell line culture

Human gastric carcinoma cell line MKN45, established from a poorly differentiated gastric adenocarcinoma (Japanese Collection of Research Bioresources), was grown in RPMI 1640 medium with Glutamax supplemented with 10% inactive fetal bovine serum and 1% penicillin–streptomycin. This gastric cell line was selected based on previous results from the group showing that this cell line is responsive to *H. pylori* cagA-mediated effects [22,29] and because it is possible to activate the NF-κB pathway in this cell line by TNF-alpha stimulation.

## 2.7. TNF-α stimulation and NF-κB pathway inhibition assay

One day prior to treatment, MKN45 gastric cells were seeded under standard conditions into 6-well culture plates ($3 \times 10^5$ cells/well) and in 8-well chamber slides ($1.5 \times 10^4$ cells/well) in order to reach 70–80% confluence. Cells were treated with 40 ng/ml TNF-α (Pepro-Tech Inc.) for 20 min, 2 h and 7 h, alone or in combination with 60 μM NF-κB activation inhibitor IV (481412, Calbiochem). As control, the same cell line was cultured only with 60 μM NF-κB activation inhibitor IV or without treatment, for the same time periods. For each condition tested, three biological independent experiments were performed, each with three replicates.

## 2.8. Immunofluorescence staining

Cells grown on 8-well chamber slides were fixed with 4% parafor-maldehyde for 15 min at room temperature, permeabilized in 0.1% Triton X-100 in PBS for 10 min and incubated with goat non-immune serum diluted 1:5 in PBS with 10% of BSA. Cells were then incubated during 2 h at room temperature with NF-κB p65 Rabbit mAb primary antibody (D14E12 Cell Signaling) diluted 1:150 in PBS containing 5% of BSA. Following washing with PBS, cells were incubated with Alexa Fluor 488 goat anti-rabbit immunoglobulin (Invitrogen), diluted 1:500 in PBS with 5% of BSA for 1 h at room temperature. Cells were washed in PBS, incubated with DAPI (Sigma) for 10 min and mounted in VectaShield (Vector Laboratories). Images were acquired using a Zeiss Axio cam MRm and the AxioVision Rel. 4.8 software.

### 2.9. B3GNT5 qRT-PCR

Total RNA was extracted from cell lines using TRI reagent LS (Sigma-Aldrich), according to manufacturer's protocol. RNA yield and quality were determined spectophotometrically and 5.0 μg of total RNA was reverse transcribed using Superscript III (Invitrogen), as described above. Expression of *B3GNT5* was quantified using Taqman probes, acquired as pre-developed assays from Applied Biosystems (HS00908059_m1) and normalized to the expression of the endogenous control 18S (HS99999901_s1). Each sample was amplified in triplicate in an ABI Prism 7500 (Applied Biosystems). Relative transcript levels were determined using the      CT-method. Statistical analysis was performed using GraphPad PRISM 5.0 software and significance was evaluated with Student's T-test.

### 2.10. H. pylori culture

The *H. pylori* strains 17875/Leb and 17875babA1: :kan babA2: :cam (17875babA1A2) were grown in Pylori agar (BioMérieux, Marcy l'Étoile, France) at 37 °C under microaerobic conditions. For strain 17875babA1: :kan babA2: :cam, culture media included also 20 mg/L Chloramphenicol (Sigma) and 25 mg/L Kanamycin (Sigma). The 17875/Leb strain is a spontaneous mutant that binds Le$^b$ but does not bind to sialylated antigens [11]. Clinical isolates from patients were cultured as previously described [30].

### 2.11. Immunoblot for BabA, BabB and SabA outer membrane proteins

Bacteria were collected from plates using 1 mL PBS and centrifuged at 2400 g for 5 min; proteins were extracted with the lysis buffer RIPA containing 1 mM PMSF, 1 mM $Na_3VO_4$, and protease inhibitor cocktail. Protein concentration was determined using the BCA protein assay kit and 50 μg was loaded in acrylamide gel (stacking 5%/resolving 10%) for electrophoresis. Proteins were transferred to immunoblot polyvinylidene difluoride membranes (Hybond-P PVDF Membrane, Amersham Biosciences) at 50 V for 1 h. Membranes were blocked for 1 h in PBS-Tween containing 5% nonfat dried milk prior to incubation overnight at 4 °C with either BabA (AK277 1:10,000), BabB (AK276 1:3000) or SabA (AK278 1:5000) antibodies [31]. Blots were incubated with a HRP-conjugated goat anti-rabbit antibody (Santa Cruz Biotechnology) and finally developed with ECL (Amersham ECL Western Blotting detection reagents).

### 2.12. H. pylori binding assay to human gastric mucosa

Labeling with FITC and adhesion assays were performed as previously described [8,10,11]. Evaluation of bacterial binding was estimated by the number of adhered bacteria to superficial foveolar epithelium region under 200× magnification. Three independent gastric biopsies tissue samples were considered for each biological group and at least 24 different fields from each section were quantified using the ImageJ software. Statistical analysis was performed using GraphPad PRISM 5.0 software and significance was evaluated by one-way ANOVA with Dunnett's Multiple Comparison Test (95% confidence interval).

## 3. Results

### 3.1. H. pylori chronic infection induces the expression of alpha2,3-sialylated antigens in human gastric mucosa

The expression of the type 1 and type 2 $\alpha$2,3-sialylated antigens, sialyl-Le[a] and sialyl-Le[x] respectively, was evaluated by tissue immunolabeling in a series of 50 gastric biopsies that have been characterized regarding gastric tissue histopathological features and genetic characteristics of *H. pylori* infecting strains (Supplementary Table 1).

As represented in Fig. 1, the majority of the non-infected gastric mucosa showed no expression of sialylated-Lewis antigens, whereas most of the *H. pylori* infected individuals presented both sialyl-Le[a] (85%) and sialyl-Le[x] (85%) staining, demonstrating that the expression of these $\alpha$2,3-sialylated structures is significantly associated with *H. pylori* infection status (p-value < 0.0001) (Fig. 1B, C, Supplementary Table 3). The pattern of staining with CA19.9 (anti-sialyl-Le[a] mAb) and KM93 (anti-sialyl-Le[x] mAb) was similar. Both antibodies showed immunoreactivity in surface mucous cells as well as in few cells from the antrum glands. Though, the extent and intensity of sialyl-Le[x] staining was higher, in comparison with sialyl-Le[a], with strong apical labeling of most surface epithelial cells lining the gastric mucosa (Fig. 1B). No differences were observed regarding the pattern of expression of sialylated antigens in paraffin and frozen sections (data not shown).

Our results suggest that the expression of $\alpha$2,3-sialylated-Lewis antigens is independent of the *cagA* status of the infecting strain, since individuals infected with either *cagA*-positive or *cagA*-negative strains presented significantly higher levels of both sialyl-Le[a] and sialyl-Le[x] than the non-infected samples (Fig. 1B, C and Supplementary Table 3).

In addition, the expression of $\alpha$2,6-sialylated antigens was evaluated using the SNA lectin in a subseries of 15 biopsies including 5 controls and 10 *H. pylori* infected individuals (5 *cagA* + and 5 *cagA* −). No strong binding of $\alpha$2,6-specific SNA lectin was observed in gastric tissue from both controls and infected individuals (Supplementary Fig. 1). A weak positive staining was observed in rare epithelial cells of 3 *H. pylori* negative and 1 *H. pylori* infected samples. As expected, SNA positivity was observed in inflammatory cells of the gastric mucosa (Supplementary Fig. 1).

### 3.2. Transcriptional up-regulation of glycosyltransferase genes by H. pylori chronic infection

To determine how *H. pylori* chronic infection and mucosal inflammation regulate the human enzymatic pathways that define the gastric glycophenotype, we have evaluated the transcript abundance of 19 glycosyltransferases involved in glycan biosynthesis (Fig. 2A), in gastric biopsies from healthy and *H. pylori* infected individuals. This analysis included a subseries of 24 individuals (*H. pylori* negative n = 8 and *H. pylori* positive n = 16) from which frozen gastric biopsies were available (Supplementary Table 1). The transcriptional analysis was designed to take into consideration the representation of epithelial cells in the biopsies samples by normalization using the epithelial marker cytokeratin 18 (KRT18).

The evaluation of the expression of the β1,3-*N*-acetylglucosaminyltransferase (*B3GnTs*) family of genes showed that *B3GNT5* transcript expression was significantly increased in *H. pylori* infected individuals (p < 0.001), whereas the relative transcript levels of *B3GNT1*, *2*, *3* and *4* were similar in the two biological groups (Fig. 2A, B).

In addition, the transcriptomic analysis of gastric biopsies showed that *H. pylori* infected individuals presented significantly higher transcript levels of the β1,3-galactosyltransferase 5 gene (*B3GALT5*) (p < 0.001), that encodes a Gal-transferase involved in the addition of a galactose residue to nascent type 1 chains (Fig. 2A, B and C).

The terminal modification of Lewis antigens structures is mediated by sialyl- and fucosyltransferases (Fig. 2C). We have analyzed the expression of all members of the β-galactoside α2,3-sialyltransferase family (*ST3GalTs*), and only *ST3GAL5* gene showed different expression in the two biological groups, with *H. pylori* infected individuals presenting significantly higher transcript levels than the controls (p < 0.05) (Fig. 2A, B).

Regarding the α1,2-(*FUT2*) and α1,3/4-(*FUT3, FUT4, FUT6, FUT9, FUT10* and *FUT11*) fucosyltransferase families, responsible for terminal fucosylation, our analysis showed that only *FUT3* expression was significantly increased in *H. pylori* infected individuals (p < 0.05) (Fig. 2A, B).

### 3.3. Gastric mucosal local transcript levels of proinflammatory cytokines

To assess the inflammatory status of the gastric mucosa samples, we evaluated the transcript levels of proinflammatory markers described to be induced by *H. pylori* infection. As expected, we observed that, despite inter-individual variation, *H. pylori* infected individuals present a markedly enhanced inflammatory profile, with significantly higher transcript levels of IL-6, IL-8, TNF-α and IFN-μ molecules (Fig. 3). Importantly, and in agreement with the histology data on inflammation and infiltration of polymorphonuclear cells, individuals in the non-infected group presented barely detectable levels of these proinflammatory molecules (Fig. 3 and Supplementary Table 1). No significant differences were observed for IL-1β transcript levels in the two biological groups (Fig. 3).

### 3.4. Effect of TNF-α induced activation of NF-κB pathway on transcriptional regulation of B3GNT5

The increased levels of TNF-α detected on gastric mucosa from *H. pylori* infected individuals (Fig. 3) were consistent with our previous data demonstrating that exposure of gastric epithelial cells to this proinflammatory cytokine led to increase expression of *B3GNT5* [22]. We further investigated the involvement of NF-κB pathway on the expression of *B3GNT5*, as a downstream response to TNF-α activation.

*In silico* analysis showed that a CpG island is predicted to exist in the 5' start of the *B3GNT5* gene (chr 3: 182970925–182972635, Fig. 4A, Ensembl v75 [27]). This sequence, putatively encompassing the B3GNT5 promoter region [32], was shown to include several putative binding sites for the transcription factors NF-κB and NF-κB1 (2 and 4 predicted binding sites, Fig. 4A1, 2 [28]). Moreover, such binding sites were predicted to correspond to open chromatin areas, as pointed out by the presence of overlapping DNase-I

hypersensitive sites [27], suggesting availability for transcription factor binding (Fig. 4A2). Additionally, most of the putative binding sites identified corresponded to sequences highly conserved between the genomes of human and five primates, an important indicator of biological functional relevance (Fig. 4A5). Comparative analysis of human and mouse genomes indicated that sequence conservation was reduced, suggesting a potential for differential regulation in distant species.

TNF-α treatment of MKN45 gastric cells resulted in nuclear translocation of the p65 NF-κB subunit (Fig. 4B). The intensity of p65 nuclear staining was higher at 2 and 7 h after TNF-α addition to the cells culture medium and at these two time-points a 4-fold increase in *B3GNT5* gene expression was observed (Fig. 4C).

Concomitant treatment of MKN45 cells with TNF-α and NF-κB activation inhibitor IV (481412) efficiently inhibited p65 nuclear translocation at the 2 and 7 h time-points (Fig. 4B). Furthermore, evaluation of *B3GNT5* transcript levels showed that NF-κB activation inhibitor IV led to a significant impairment of TNF-α-mediated up-regulation of *B3GNT5* transcription, and this effect was more pronounced at 7 h post treatment with NF-κB activation inhibitor IV (Fig. 4C). The p65 nuclear staining observed at the 20 min time-point in the presence of the inhibitor, reflects the lack of the required time for suppression of NF-kappaB signaling and as expected at this time point *B3GNT5* transcription levels were not reduced. MKN45 cells treated only with NF-κB activation inhibitor IV were similar to control cells in all assays.

### 3.5. Gastric mucosa sialylation controls SabA-mediated H. pylori adhesion

Immunoblot analysis of *H. pylori* clinical isolates from chronically infected subjects showed that most strains presented the expression of both BabA and BabB proteins (Fig. 5A). Expression of the sialic acid binding adhesin, SabA, was more heterogeneous among the clinically isolated strains, with 13 out 25 strains showing very low levels or absence of SabA protein expression. For some clinical isolates a double band was observed, this may stem from variations in protein size. No association was observed between SabA expression, evaluated by immunoblot analysis of clinical isolates in *in vitro* cultures, and sialyl-Le[a/x] expression in the gastric tissue from the corresponding subject (Fig. 5A).

In order to understand the impact of the altered glycophenotype induced upon *H. pylori* infection on bacterial attachment to inflamed gastric mucosa, we further evaluated the adhesion of fluorescein-labeled bacteria to gastric biopsies. We have used two previously described model strains, the *17875babA1A2* mutant which lacks BabA and therefore adherence is mediated by the SabA adhesin, and the 17875/Leb spontaneous mutant strain that expresses a functional BabA adhesin but it is unable to bind sialylated structures [11]. As shown in Fig. 5 (B and C), the *17875babA1A2* strain (SabA competent) adhered significantly more to the surface mucous cells and glands of gastric mucosa from *H. pylori* infected individuals displaying sialylated antigen expression (b, c), than to tissue sections from non-infected subjects without sialylated antigens expression (a) (p < 0.001). In contrast, the strain 17875/Leb (BabA competent), adhered to a similar extent to gastric mucosa from non-infected and *H. pylori* infected individuals (d, e, f), independent of the sialylation patterns of the gastric mucosa (Fig. 5B, C). Despite lack of association between

SabA expression and mucosal expression of sialylated antigens, we observe that SabA-mediated binding is significantly associated with sialylated antigens expression. These results are in agreement with previous data showing that SabA binding is associated with sialyl-Le$^x$ expression levels and several markers of tissue inflammation [11].

## 4. Discussion

In the present study, we demonstrate that *H. pylori* chronic infection results in a remodeling of the gastric mucosa glycosylation profile, with de novo expression of the α2,3-sialylated structures, sialyl-Le$^a$ and sialyl-Le$^x$. In agreement with our data, the increased expression of α2,3-sialylated structures in response to *H. pylori* has been described to occur in humans [11,17] and in different animal models of infection [11,33–35]. Noteworthy, no alteration in α2,6-sialylated glycans [36] was observed, when comparing infected individuals and controls, supporting that *H. pylori* specifically promotes α2,3-sialylated antigens biosynthesis.

The biosynthesis of terminal sialylated Lewis structures is dependent on the coordinated activity of several glycosyltransferases. We have previously shown, using *in vitro* gastric cell line models, that *H. pylori* is able to induce *B3GNT5* expression [22]. This observation is now validated in the context of human *H. pylori* chronic infection by the demonstration that gastric biopsies from *H. pylori* infected individuals present significantly higher transcript levels of *B3GNT5* (Fig. 2A, B). The *B3GNT5* gene encodes a glycosyltransferase responsible for transfer a *N*-acetylglucosamine (GlcNAc) to galactose (Gal), leading to the biosynthesis of lactotriaosylceramide (Lc$_3$Cer: GlcNAc(β1,3)Gal(β1,4)Glc-ceramide), the precursor structure of lacto- (type 1) and neolacto-series (type 2) carbohydrate chains on glycosphingolipids (Fig. 2C) [37,38]. Importantly, *B3gnt5*-deficient mice, completely lack Lc$_3$Cer synthase activity, demonstrating that β3GnT5 expression is required for lacto/neolacto-series glycosphingolipids biosynthesis [39]. It was also shown that sialyl-Le$^x$ biosynthesis in human colon cancer cells is determined by Lc$_3$Cer precursor backbone chain biosynthesis [40,41]. In agreement, we have demonstrated *in vitro* that overexpression of β3GnT5 is sufficient to increase sialyl-Le$^x$ expression [22]. Interestingly, *in vitro* we observed that β3GnT5 induction was associated with the *H. pylori cagA* status, however in the mucosal samples such association was not observed, indicating that within the gastric microenvironment, *B3GNT5* transcription is not strictly dependent on CagA injection and that in the context of chronic infection *B3GNT5* expression can be induced by the host inflammatory response. This observation further suggests that *in vitro* models of infection due to lack of inflammatory context may have limitations and supports the importance of validation using clinical samples.

In addition *H. pylori* infected subjects showed an up-regulation of the *B3GALT5* gene (Fig. 2A, B). Enhanced expression of β1,3-galactosyltransferase 5 (β3GalT5) has been reported to result in increased biosynthesis of extended type 1 chains on lactosylceramides and glycoproteins in colon carcinoma cells [42,43], while suppression of β3GalT5 in pancreas adenocarcinoma cells reduced the expression of sialyl-Le$^a$ [44]. In line with these observations, the induction of β3GalT5, in response to *H. pylori* infection, can drive the

extension of precursor chains towards the biosynthesis of type 1 sequences, therefore contributing for the increased expression of sialyl-Le[a] (Fig. 2C).

The transfer of sialic acid to terminal Gal on Lewis structures is mediated by α2,3-sialyltransferases. The ST3Gal III preferentially uses type 1 chains as acceptors leading to sialyl-Le[a] biosynthesis, whereas ST3Gal IV and ST3Gal VI modify preferentially type 2 sequences to produce sialyl-Le[x] [45]. No differences were observed regarding the transcript levels of the genes encoding these enzymes in gastric biopsies, and in *H. pylori* infected gastric cell lines [22], supporting the hypothesis that it is the accumulation of type 1 and 2 lacto-series precursor chains, rather than increased sialylation that leads to increased expression of terminal sialylated Lewis structures in response to infection. Noteworthy, we observed that *ST3GAL5* transcription was up-regulated in *H. pylori* infected individuals (Fig. 2A, B). This gene encodes a sialyltransferase, ST3Gal V, described to use almost exclusively lactosylceramide (LacCer) as acceptor, leading to GM3 ganglioside biosynthesis (Fig. 2C) [45]. Although GM3 ganglioside is not involved in *H. pylori* binding [46,47], it was demonstrated that GM3 has a good neutralizing capacity against the *H. pylori* vacuolating toxin VacA, preventing its entrance into the gastric cells [48]. Hence, the induction of *ST3GAL5* may reflect a host response to decrease the epithelial damage associated with the infection.

Our data shows that *H. pylori* infected individuals also present significantly higher transcript levels of *FUT3* (Fig. 2A, B), whereas no alterations in transcript levels were observed in any of the other fucosyltransferases. The increased expression of *FUT3* is biologically relevant since α1,3/4-fucosylation of sialyl-lactose and sialyl-lactosamine is known to lead to the biosynthesis of sialyl-Le[a/x] (Fig. 2C) and these structures have been demonstrated to be better receptors for *H. pylori* than its precursor non-fucosylated glycan chains [49]. The up-regulation of sialyl-Le[x] expression in the gastrointestinal tissue, particularly in colon, may also be attributed to decreased expression of the B4GALNT2 glycosyltransferase, responsible for Sd[a] antigen biosynthesis [50,51]. Further evaluation of the relevance of this molecular mechanism during gastric carcinogenesis remains to be fully addressed [51].

There is a large collection of data supporting that modulation of host glycosylation profile is associated with infection and host inflammatory response [52]. Chronic gastric inflammation induced by *H. pylori* is characterized by the up-regulation of diverse cytokines and chemokines [53].

The transcriptomic analysis showed that *H. pylori* infected individuals present a local enrichment in the proinflammatory cytokines IL-6, IL-8, TNF-α and IFN-γ (Fig. 3), that was accompanied by the recruitment of inflammatory cells to the inflamed tissue (Supplementary Table 1). We did not observe a significant up-regulation of IL-1β transcript levels (Fig. 3), in contrast with the moderate increase previously reported in gastric mucosal samples of *H. pylori* infected individuals [54,55].

Based on our previous observations that TNF-α stimulation of gastric epithelial cells resulted in increased *B3GNT5* expression [22], we have investigated the molecular mechanism underlying TNF-mediated induction of *B3GNT5*. TNF-α is recognized as a

potent activator of the canonical NF-κB pathway [56]. Moreover, according to our bioinformatic analysis, the predicted *B3GNT5* promoter sequence presents several highly conserved putative binding sites for NF-κB transcription factors in open chromatin areas (Fig. 4A). Under resting conditions NF-κB complexes are known to be sequestered in the cytoplasm by inhibitory IκB proteins [56]. Upon stimulation, namely by tumor necrosis factor receptors family signaling upon TNF-α binding, IκB is phosphorylated and targeted for proteosomal degradation, releasing p65-containing heterodimers to translocate to the nucleus and stimulate the transcription of specific genes [56]. Several reports have described activation of the NF-κB pathway in response to *H. pylori* infection and inflammation [57]. Additionally, we have previously shown that *H. pylori* infection results in induction of several genes downstream of the NF-κB pathway in gastric cells [22]. We demonstrated that inhibition of the NF-κB pathway, assessed by the impairment of p65 nuclear translocation, antagonized the effect of TNF-α on activation of *B3GNT5* transcription (Fig. 4B, C). In line with our observations, a global gene expression analysis showed that blocking of NF-κB-mediated responses in endothelial cells led to the down-regulation of *B3GNT5* [58]. Altogether, these data indicate that the increased expression of *B3GNT5* induced by TNF-α is mediated through activation of the NF-κB pathway (Fig. 6).

Long-term colonization of the gastric mucosa and the establishment of a chronic infection are dependent on balanced adaptation of both host and *H. pylori* [59]. *H. pylori* exploits multiple glycan targets to efficiently colonize the gastric mucosa, taking benefit of a large collection of outer membrane proteins presenting lectin activity, namely the BabA, LabA and SabA adhesins. Moreover, *H. pylori* adherence features are known to be dynamic, allowing the bacteria to adapt to gastric microenvironment changes, such as altered glycosylation profiles [11]. In our analysis, 48% of the clinical *H. pylori* isolates present SabA protein expression (Fig. 5A), which is in accordance with the SabA expression frequency described on European populations [11,31,49]. Importantly, SabA expression has been demonstrated to be subject to a dynamic on–off switching regulated by different genetic mechanisms, including slipped-strand mispairing (SSM) [11], a repetitive DNA element regulation by a rheostat-like mechanism [60], gene duplication by gene conversion [61], and by the acid-responsive signal (ArsRS) two component signal transduction regulatory system [62]. This rapid switch of SabA expression may explain the lack of association between SabA protein expression and sialyl-Le[a] and sialyl-Le[x] tissue levels (Fig. 5A). While the individual gastric sialylation glycome is maintained once a chronic infection is established, the SabA expression is expected to differ within an individual over time.

We have further evaluated the impact of increased sialylation, observed in *H. pylori* chronically infected patients, on bacterial attachment to gastric mucosa. Our results demonstrated that adhesion of 17875babA1A2 strain, expressing an active SabA adhesin, was significantly higher in gastric tissue samples displaying higher sialyl-Le[a/x] expression (Fig. 5B, C). This higher binding potential can be attributed to SabA-mediated binding to sialylated receptors since adhesion of a strain lacking a functional SabA adhesin, 17875/Leb strain, showed no differences in adhesion. SabA-mediated adhesion to inflamed gastric mucosa is particularly relevant, since this adhesin binds sialylated antigens mainly present on membrane glycosphingolipids [11], therefore promoting a more intimate contact between

the bacteria and the host cells for a tighter fit of the infection load and efficient transfer of bacterial virulence factors (Fig. 6).

## 5. Conclusions

In summary, we demonstrate, for the first time, in human gastric biopsies that *H. pylori* exploits the tightly regulated host cell glycosyla-tion machinery inducing the expression of *B3GNT5, B3GALT5* and *FUT3* and leading to biosynthesis of SabA-ligands. Furthermore, we show that up-regulation of *B3GNT5*, which encodes a key enzyme in inflammation-driven gastric glycophenotype modulation, results from TNF-α-mediated activation of the NF-κB pathway. Finally, our results demonstrate that modulation of the host gastric glycosylation profile favors *H. pylori* chronic infection by contributing to bacterial epithelial attachment to inflamed gastric mucosa.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

## References

1. Correa P, Houghton J. Carcinogenesis of *Helicobacter pylori*. Gastroenterology. 2007; 133:659–672. [PubMed: 17681184]

2. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, DM.; Forman, D.; Bray, F. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, IARC CancerBase No 11. Vol. 1.0. International Agency for Researh on Cancer; Lyon, France: 2013.

3. Wroblewski LE, Peek RM, Wilson KT. *Helicobacter pylori* and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010; 23:713–739. [PubMed: 20930071]

4. Hatakeyama M. *Helicobacter pylori* CagA and gastric Cancer: a paradigm for hit-and-run carcinogenesis. Cell Host & Microbe. 2014; 15:306–316. [PubMed: 24629337]

5. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with *Helicobacter pylori* strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995; 55:2111–2115. [PubMed: 7743510]

6. Enroth H, Kraaz W, Engstrand L, Nyrén O, Rohan T. *Helicobacter pylori* strain types and risk of gastric cancer: a case–control study. Cancer Epidemiol Biomarkers Prev. 2000; 9:981–985. [PubMed: 11008919]

7. Magalhães A, Ismail MN, Reis CA. Sweet receptors mediate the adhesion of the gastric pathogen *Helicobacter pylori*: glycoproteomic strategies. Expert Rev Proteomics. 2010; 7:307–310. [PubMed: 20536299]

8. Azevedo M, Eriksson S, Mendes N, Serpa J, Figueiredo C, Resende LP, Ruvoën-Clouet N, Haas R, Borén T, Pendu JL, David L. Infection by *Helicobacter pylori* expressing the BabA adhesin is influenced by the secretor phenotype. J Pathol. 2008; 215:308–316. [PubMed: 18498114]

9. Ilver D, Arnqvist A, Ogren J, Frick I-M, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Boren T. *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998; 279:373–377. [PubMed: 9430586]

10. Magalhaes A, Gomes J, Ismail MN, Haslam SM, Mendes N, Osorio H, David L, Le Pendu J, Haas R, Dell A, Boren T, Reis CA. Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated *Helicobacter pylori* adhesion to gastric mucosa. Glycobiology. 2009; 19:1525–1536. [PubMed: 19706747]

11. Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson K-A, Altraja S, Wadstrom T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson K-E, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T. *Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation. Science. 2002; 297:573–578. [PubMed: 12142529]

12. Bäckström A, Lundberg C, Kersulyte D, Berg DE, Borén T, Arnqvist A. Metastability of *Helicobacter pylori* bab adhesin genes and dynamics in Lewis b antigen binding. Proc Natl Acad Sci U S A. 2004; 101:16923–16928. [PubMed: 15557006]

13. Rossez Y, Gosset P, Boneca IG, Magalhães A, Ecobichon C, Reis CA, Cieniewski-Bernard C, Joncquel Chevalier Curt M, Léonard R, Maes E, Sperandio B, Slomianny C, Sansonetti PJ, Michalski JC, Robbe-Masselot C. The LacdiNAc-specific adhesin LabA mediates adhesion of *Helicobacter pylori* to human gastric mucosa. J Infect Dis. 2014; 210:1286–1295. [PubMed: 24755437]

14. Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, Borén T, Haas R, Sasakawa C, Mimuro H. BabA-mediated adherence is a potentiator of the *Helicobacter pylori* Type IV secretion system activity. J Biol Chem. 2011; 286:25256–25264. [PubMed: 21596743]

15. Brandt S, Kwok T, Hartig R, König W, Backert S. NF-κB activation and potentiation of proinflammatory responses by the *Helicobacter pylori* CagA protein. Proc Natl Acad Sci U S A. 2005; 102:9300–9305. [PubMed: 15972330]

16. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Memet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL. Nod1 responds to peptidoglycan delivered by the *Helicobacter pylori* cag pathogenicity island. Nat Immunol. 2004; 5:1166–1174. [PubMed: 15489856]

17. Ota H, Nakayama J, Momose M, Hayama M, Akamatsu T, Katsuyama T, Graham DY, Genta RM. *Helicobacter pylori* infection produces reversible glycosylation changes to gastric mucins. Virchows Arch. 1998; 433:419–426. [PubMed: 9849856]

18. Pinho SS, Carvalho S, Marcos-Pinto R, Magalhães A, Oliveira C, Gu J, Dinis-Ribeiro M, Carneiro F, Seruca R, Reis CA. Gastric cancer: adding glycosylation to the equation. Trends Mol Med. 2013; 19:664–676. [PubMed: 23932995]

19. Colomb F, Krzewinski-Recchi MA, El Machhour F, Mensier E, Jaillard S, Steenackers A, Harduin-Lepers A, Lafitte JJ, Delannoy P, Groux-Degroote S. TNF regulates sialyl-Lewisx and 6-sulfo-sialyl-Lewisx expression in human lung through up-regulation of ST3GAL4 transcript isoform BX. Biochimie. 2012; 94:2045–2053. [PubMed: 22691873]

20. Colomb F, Vidal O, Bobowski M, Krzewinski-Recchi MA, Harduin-Lepers A, Mensier E, Jaillard S, Lafitte JJ, Delannoy P, Groux-Degroote S. TNF induces the expression of the sialyltransferase ST3Gal IV in human bronchial mucosa via MSK1/2 protein kinases and increases FliD/sialyl-Lewis(x)-mediated adhesion of *Pseudomonas aeruginosa*. Biochem J. 2014; 457:79–87. [PubMed: 24099577]

21. Delmotte P, Degroote S, Lafitte J-J, Lamblin G, Perini J-M, Roussel P. Tumor necrosis factor α increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa. J Biol Chem. 2002; 277:424–431. [PubMed: 11679593]

22. Marcos N, Magalhães A, Ferreira B, Oliveira M, Carvalho A, Mendes N, Gilmartin T, Head S, Figueiredo C, David L, Santos-Silva F, Reis C. *Helicobacter pylori* induces beta3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J Clin Invest. 2008; 118:2325–2336. [PubMed: 18483624]

23. Marcos-Pinto R, Carneiro F, Dinis-Ribeiro M, Wen X, Lopes C, Figueiredo C, Machado JC, Ferreira RM, Reis CA, Ferreira J, Pedroto I, Areias J. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther. 2012; 35:1451–1459. [PubMed: 22548492]

24. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn L-J, Carneiro F, Sobrinho-Simões M. *Helicobacter pylori* and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002; 94:1680–1687. [PubMed: 12441323]

25. Lofling J, Holgersson J. Core saccharide dependence of sialyl Lewis X biosynthesis. Glycoconj J. 2009; 26:33–40. [PubMed: 18607721]

26. Nairn, AV.; dela Rosa, M.; Moremen, KW. Transcript analysis of stem cells. In: Minoru, F., editor. Methods Enzymol. Vol. 479. Academic Press; 2010. p. 73-91.

27. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Girón CG, Gordon L, Hourlier T, Hunt S, Johnson N, Juettemann T, Kähäri AK, Keenan S, Kulesha E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ruffier M, Sheppard D, Taylor K, Thormann A, Trevanion SJ, Vullo A, Wilder SP, Wilson M, Zadissa A, Aken BL, Birney E, Cunningham F, Harrow J, Herrero J, Hubbard TJP, Kinsella R, Muffato M, Parker A, Spudich G, Yates A, Zerbino DR, Searle SMJ. Ensembl 2014. Nucleic Acids Res. 2014; 42:D749–D755. [PubMed: 24316576]

28. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003; 31:3651–3653. [PubMed: 12824386]

29. Magalhães A, Marcos NT, Carvalho AS, David L, Figueiredo C, Bastos J, David G, Reis CA. *Helicobacter pylori* cag pathogenicity island-positive strains induce syndecan-4 expression in gastric epithelial cells. 2009

30. Ferreira RM, Machado JC, Letley D, Atherton JC, Pardo ML, Gonzalez CA, Carneiro F, Figueiredo C. A novel method for genotyping the *Helicobacter pylori* vacA intermediate region directly in gastric biopsy specimens. J Clin Microbiol. 2012; 50:3983–3989. [PubMed: 23035185]

31. Odenbreit S, Swoboda K, Barwig I, Ruhl S, Borén T, Koletzko S, Haas R. Outer membrane protein expression profile in *Helicobacter pylori* clinical isolates. Infect Immun. 2009; 77:3782–3790. [PubMed: 19546190]

32. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011; 25:1010–1022. [PubMed: 21576262]

33. Gomes J, Magalhães A, Carvalho AS, Hernandez GE, Papp SL, Head SR, Michel V, David L, Gärtner F, Touati E, Reis CA. Glycophenotypic alterations induced by *Pteridium aquilinum* in mice gastric mucosa: synergistic effect with *Helicobacter pylori* infection. PLoS ONE. 2012; 7:e38353. [PubMed: 22719879]

34. Lindén S, Mahdavi J, Semino-Mora C, Olsen C, Carlstedt I, Borén T, Dubois A. Role of ABO secretor status in mucosal innate immunity and *H. pylori* infection. PloS Pathog. 2008; 4:006–0013.

35. Ohno T, Vallström A, Rugge M, Ota H, Graham DY, Arnqvist A, Yamaoka Y. Effects of blood group antigen-binding adhesin expression during *Helicobacter pylori* infection of Mongolian gerbils. J Infect Dis. 2011; 203:726–735. [PubMed: 21227917]

36. Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden ECMB, Anderson D, McClure H, Varki A, Varki NM. Human-specific regulation of $\alpha$2-6-linked sialic acids. J Biol Chem. 2003; 278:48245–48250. [PubMed: 14500706]

37. Togayachi A, Akashima T, Ookubo R, Kudo T, Nishihara S, Iwasaki H, Natsume A, Mio H, Inokuchi J-i, Irimura T, Sasaki K, Narimatsu H. Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide $\beta$1,3-N-acetylglucosaminyltransferase ($\beta$3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids. J Biol Chem. 2001; 276:22032–22040. [PubMed: 11283017]

38. Henion TR, Zhou D, Wolfer DP, Jungalwala FB, Hennet T. Cloning of a mouse β1,3 N-acetylglucosaminyltransferase GlcNAc(β1,3)Gal(β1,4)Glc-ceramide synthase gene encoding the key regulator of Lacto-series glycolipid biosynthesis. J Biol Chem. 2001; 276:30261–30269. [PubMed: 11384981]

39. Togayachi A, Kozono Y, Ikehara Y, Ito H, Suzuki N, Tsunoda Y, Abe S, Sato T, Nakamura K, Suzuki M, Goda HM, Ito M, Kudo T, Takahashi S, Narimatsu H. Lack of lacto/neolacto-glycolipids enhances the formation of glycolipid-enriched micro-domains, facilitating B cell activation. Proc Natl Acad Sci U S A. 2010; 107:11900–11905. [PubMed: 20547865]

40. Holmes EH, Ostrander GK, Clausen H, Graem N. Oncofetal expression of Lex carbohydrate antigens in human colonic adenocarcinomas. Regulation through type 2 core chain synthesis rather than fucosylation. J Biol Chem. 1987; 262:11331–11338. [PubMed: 3112156]

41. Holmes EH, Hakomori S, Ostrander GK. Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed beta 1-3N-acetylglucosaminyltransferase. J Biol Chem. 1987; 262:15649–15658. [PubMed: 2960671]

42. Lin C-H, Fan Y-Y, Chen Y-Y, Wang S-H, Chen C-I, Yu L-C, Khoo K-H. Enhanced expression of β3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines. Glycobiology. 2009; 19:418–427. [PubMed: 19136585]

43. Salvini R, Bardoni A, Valli M, Trinchera M. β1,3-Galactosyltransferase β3Gal-T5 Acts on the GlcNAcβ1 → 3Galβ1 → 4GlcNAcβ1 → R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocar-cinomas. J Biol Chem. 2001; 276:3564–3573. [PubMed: 11058588]

44. Mare L, Trinchera M. Suppression of β1,3galactosyltransferase β3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans. Eur J Biochem. 2004; 271:186–194. [PubMed: 14686931]

45. Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, Foulquier F, Groux-Degroote S, Delannoy P. Sialyltransferases functions in cancers. Front Biosci (Elite Ed). 2012; 4:499–515. [PubMed: 22201891]

46. Roche N, Ångström J, Hurtig M, Larsson T, Borén T, Teneberg S. *Helicobacter pylori* and complex gangliosides. Infect Immun. 2004; 72:1519–1529. [PubMed: 14977958]

47. Roche N, Larsson T, Ångström J, Teneberg S. *Helicobacter pylori*-binding ganglio-sides of human gastric adenocarcinoma. Glycobiology. 2001; 11:935–944. [PubMed: 11744628]

48. Wada A, Hasegawa M, Wong P-F, Shirai E, Shirai N, Tan L-J, Llanes R, Hojo H, Yamasaki E, Ichinose A, Ichinose Y, Senba M. Direct binding of gangliosides to *Helicobacter pylori* vacuolating cytotoxin (VacA) neutralizes its toxin activity. Glycobiology. 2010; 20:668–678. [PubMed: 20118071]

49. Aspholm M, Olfat FO, Nordén J, Sondén B, Lundberg C, Sjostrom R, Altraja S, Odenbreit S, Haas R, Wadstrom T, Engstrand L, Semino-Mora C, Liu H, Dubois A, Teneberg S, Arnqvist A, Borén T. SabA is the *H. pylori* hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog. 2006; 2:e110. [PubMed: 17121461]

50. Dohi T, Kawamura YI. Incomplete synthesis of the Sda/Cad blood group carbohydrate in gastrointestinal cancer. Biochim Biophys Acta. 2008; 1780:467–471. [PubMed: 17961927]

51. Groux-Degroote S, Wavelet C, Krzewinski-Recchi MA, Portier L, Mortuaire M, Mihalache A, Trinchera M, Delannoy P, Malagolini N, Chiricolo M, Dall'Olio F, Harduin-Lepers A. B4GALNT2 gene expression controls the biosynthesis of Sda and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract. Int J Biochem Cell Biol. 2014; 53:442–449. [PubMed: 24953560]

52. Kreisman LS, Cobb BA. Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis. Glycobiology. 2012; 22:1019–1030. [PubMed: 22492234]

53. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007; 117:60–69. [PubMed: 17200707]

54. Basso D, Scrigner M, Toma A, Navaglia F, Di Mario F, Rugge M, Plebani M. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res. 1996; 26:207–210. [PubMed: 8905454]

55. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with *Helicobacter pylori* infection. Scand J Gastroenterol. 1994; 29:425–429. [PubMed: 8036458]

56. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-[kappa]B signaling pathways. Nat Immunol. 2011; 12:695–708. [PubMed: 21772278]

57. Lamb A, Chen L-F. The many roads traveled by *Helicobacter pylori* to NF-κB activation. Gut Microbes. 2010; 1:109–113. [PubMed: 21326919]

58. Minami T, Miura M, Aird WC, Kodama T. Thrombin-induced autoinhibitory factor, down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. J Biol Chem. 2006; 281:20503–20520. [PubMed: 16627481]

59. Salama NR, Hartung ML, Muller A. Life in the human stomach: persistence strategies of the bacterial pathogen *Helicobacter pylori*. Nat Rev Microbiol. 2013; 11:385–399. [PubMed: 23652324]

60. Aberg A, Gideonsson P, Vallstrom A, Olofsson A, Ohman C, Rakhimova L, Boren T, Engstrand L, Brannstrom K, Arnqvist A. A repetitive DNA element regulates expression of the *Helicobacter pylori* sialic acid binding adhesin by a rheostat-like mechanism. PLoS Pathog. 2014; 10:e1004234. [PubMed: 24991812]

61. Talarico S, Whitefield SE, Fero J, Haas R, Salama NR. Regulation of *Helicobacter pylori* adherence by gene conversion. Mol Microbiol. 2012; 84:1050–1061. [PubMed: 22519812]

62. Goodwin AC, Weinberger DM, Ford CB, Nelson JC, Snider JD, Hall JD, Paules CI, Peek RM, Forsyth MH. Expression of the *Helicobacter pylori* adhesin SabA is controlled via phase variation and the ArsRS signal transduction system. Microbiology. 2008; 154:2231–2240. [PubMed: 18667556]

## Abbreviations

| | |
|---|---|
| **BabA** | blood group antigen binding adhesin |
| **B3GNT5** | β1,3-*N*-acetylglucosaminyltransferase 5 |
| **B3GALT5** | β1,3-galactosyltransferase 5 |
| **FUT3** | fucosyltransferase 3 |
| ***H. pylori*** | *Helicobacter pylori* |
| **LabA** | LacdiNAc-specific adhesin |
| **Sialyl-Lea/x** | sialyl-Lewis a/x |
| **SabA** | sialic acid binding adhesin |
| **SNA** | *Sambucus nigra* lectin |

**Fig. 1.**

Chronic *H. pylori* infection of human gastric mucosa results in expression of sialylated antigens. (A) Representative micrographs of *H. pylori* visualized by modified Giemsa and (B) immunohistochemical detection of sialyl-Le$^a$ and sialyl-Le$^x$ antigens in paraffin-embedded sections of human gastric mucosa from non-infected individuals (*H. pylori*−) and individuals infected with either cagA-positive (*H. pylori*+/*cagA*+) or *cagA*-negative (*H. pylori*+/*cagA*−) strains. Magnification 200× with inserts of 400×. No major differences were observed regarding the pattern of expression of sialylated antigens in paraffin and frozen sections (data not shown). (C) Graphical representation of sialyl-Le$^a$ and sialyl-Le$^x$ antigen

expression in the three biological groups, statistical significance determined using the Fisher's exact test $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$.

**Fig. 2.**
Transcriptomic analysis of glycosyltransferase genes involved in biosynthesis of glycan
chains in human gastric mucosa. (A) qRT-PCR analysis of glycosyltransferases, including
GalNAc-transferases, Gal-transferases, Sialyl-transferases and Fucosyl-transferases in
human gastric biopsies. Each bar represents the mean value of relative transcript abundance
considering all individuals within each biological group and error bars represent the standard
deviation. (B) qRT-PCR analysis of *B3GNT5, B3GALT5, ST3GAL5* and *FUT3* genes. The
box and whisker plots represent relative gene transcript abundance for each biological group
including the minimum and maximum values and the median. qRT-PCR reactions were
performed in triplicate and relative transcript abundance of the target gene was normalized
to *KRT18* expression levels. Statistical significance determined using unpaired t-test with
Welch correction.*p < 0.05 and **p < 0.001. (C) Cartoon representation of the pathways
involved in the biosynthesis of sialylated-Lewis type 1/2 chains in glycosphingolipids. The

genes represented in these pathways that are shown to be induced in response to *H. pylori* infection are represented in red. Some of the enzymes depicted in the scheme involved in terminal sialylation and fucosylation may also use as acceptors type 1/2 chains on glycoproteins (not represented in this cartoon).

**Fig. 3.**
Gastric mucosal local transcript levels of inflammatory markers. qRT-PCR analysis of *IL-1β, IL-8, IL-6, TNF-α* and *IFN-γ* genes. The box and whisker plots represent relative gene transcript abundance for each biological group including the minimum and maximum values and the median. qRT-PCR reactions were performed in triplicate and relative transcript abundance of the target gene was normalized to *KRT18* expression levels. Statistical significance determined using unpaired t-test with Welch correction.*p < 0.05.

**Fig. 4.**

Regulation of *B3GNT5* gene expression. (A) Schematic representation of *B3GNT5* gene structure (A1: white boxes for untranslated regions, gray box for protein-coding regions [27]) and predicted CpG island (A2 [27]), showing 6 putative NF-κB (in dark blue) or NF-κB1 binding sites (in light blue, A3), all of which overlapping with open chromatin areas according to DNAse I hypersensitivity sites (in green, A4 [27]). Also displayed are the results for the NF-κB or NF-κB1 putative binding sites sequence conservation analysis across human, 5 primates and mouse: in red, conserved nucleotides; in black, nucleotides or gaps not conserved with the human sequence (*Hs* for *Homo sapiens, Pt* for *Pan troglodytes, Gg* for *Gorilla gorilla, Pa* for *Pongo abelii, Cj* for *Callithrix jacchus* and *Mm* for *Mus musculus*, A5). (B) Immunofluorescence labeling for p65 (NF-κB-pathway element) in

MKN45 cell line stimulated with TNF-α in the absence or presence of NF-κB activation inhibitor IV at 20 min, 2 h or 7 h time points. Cell nuclei are stained with DAPI. Magnification 630×. (C) qRT-PCR analysis of *B3GNT5* gene expression in MKN45 cell line stimulated with TNF-α in the absence or presence of NF-κB activation inhibitor IV at 20 min, 2 h or 7 h time points. The graph represents average value and SD of two independent experiments performed in triplicate. Significance was evaluated with Student's T-test. *$p < 0.05$ and **$p < 0.001$.

**Fig. 5.**
Impact of increased sialylation on *H. pylori* attachment to inflamed human gastric mucosa.
(A) Immunoblot analysis of model *H. pylori* strains and clinical isolates using BabA, BabB
and SabA recognizing antibodies, and schematic representation of sialyl-Le[a] and sialyl-Le[x]
expression in the corresponding individuals gastric biopsies (green: positive; red: negative).
(B) Adhesion of fluorescein-labeled *H. pylori* strain *17875babA1A2* (functional SabA+) and
17875/Leb (functional SabA −) to gastric mucosa tissue sections from non-infected (*H.
pylori*−) (a, d), *H. pylori* CagA(+) strains infected (*H. pylori*+/CagA+) (b, e) and *H. pylori*
CagA(−) strains infected (*H. pylori*+/CagA−) (c, f) individuals, magnification 200×. (C)
Quantification of bacterial adhesion to human gastric mucosa tissue samples, the box and
whisker plots represent the minimum and maximum values and the median of at least 24
different fields from three independent gastric biopsies for each biological group;
significance was determined by one-way ANOVA with Dunnett's Multiple Comparison
Test. ***$p < 0.001$.

**Fig. 6.**

A model for modulation of the gastric mucosal glycophenotype during *Helicobacter pylori* chronic infection and implications in bacterial adhesion and pathogenesis. In healthy gastric mucosa, *H. pylori* adhesion to the epithelial cells is mainly mediated by BabA recognition of H-type 1 (H1) and Lewis b (Le$^b$) structures present on glycoproteins (mainly mucins) expressed on gastric surface epithelium. This glycan-mediated adhesion favors translocation of bacterial virulence factors, such as CagA and peptidoglycan (PGN), through the type IV secretion system (T4SS) into the host cells, leading to the activation of several intracellular signaling pathways that culminate in activation of transcription of proinflammatory cytokines, including IL-8 and TNF-α. We propose that during chronic infection and gastric mucosa inflammation, the increased levels of TNF-α result in stimulation of the NF-κB canonical pathway, with translocation of p65 to the nucleus and activation of *B3GNT5* gene transcription. Although not depicted in this illustration, it cannot be excluded direct activation of NF-κB pathway by bacterial products (CagA, PGN) or activation by TNF-α secreted by recruited inflammatory cells. The up-regulation of β3Gnt5 activity leads to increased biosynthesis of terminal sialylated type 1/2 structures in glycosphingolipids, resulting in a remodeling of the gastric epithelial cells glycophenotype. The increased

expression of the inflammation-associated sialylated structures, recognized by the sialic acid binding adhesin (SabA), promotes a closer membrane attachment of *H. pylori* to inflamed gastric mucosa, an important feature for infection chronicity.